Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:GLMDNASDAQ:PRTGNASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.66+1.8%$0.56$0.40▼$1.17$13.69M2.2497,359 shs73,761 shsGLMDGalmed Pharmaceuticals$1.51+1.3%$1.38$1.15▼$23.80$2.50M0.511.31 million shs149,956 shsPRTGPortage Biotech$8.41+0.4%$8.03$2.10▼$23.01$8.82M0.33983,210 shs12,246 shsSNSESensei Biotherapeutics$0.34-4.7%$0.35$0.25▼$0.87$8.68M0.1897,077 shs89,305 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%-2.33%+19.84%+34.79%-23.27%GLMDGalmed Pharmaceuticals0.00%+4.86%+20.32%-20.73%-63.13%PRTGPortage Biotech0.00%+6.86%-6.76%+88.99%+52.91%SNSESensei Biotherapeutics0.00%+12.12%-7.47%-23.43%-51.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.4872 of 5 stars0.02.00.00.02.50.80.6GLMDGalmed Pharmaceuticals0.771 of 5 stars0.04.00.00.00.02.50.6PRTGPortage Biotech0.3272 of 5 stars0.04.00.00.00.01.70.0SNSESensei Biotherapeutics4.6835 of 5 stars3.75.00.04.82.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/APRTGPortage Biotech 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$4.501,207.38% UpsideCurrent Analyst Ratings BreakdownLatest GLMD, PRTG, SNSE, and AIMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.005/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/28/2025SNSESensei BiotherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$3.50 ➝ $4.003/28/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K128.86N/AN/A$5.23 per share0.13GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/APRTGPortage BiotechN/AN/A$14.50 per share0.58$3.74 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)GLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%8/26/2025 (Estimated)PRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/A-342.34%-196.47%8/13/2025 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.15N/AN/AN/AN/A-53.86%-46.91%8/5/2025 (Estimated)Latest GLMD, PRTG, SNSE, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/6/2025Q1 2025SNSESensei Biotherapeutics-$0.21-$0.27-$0.06-$0.27N/AN/A3/28/2025Q4 2024SNSESensei Biotherapeutics-$0.27-$0.27N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.501.371.33GLMDGalmed PharmaceuticalsN/A7.037.03PRTGPortage BiotechN/A3.083.08SNSESensei BiotherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AGLMDGalmed Pharmaceuticals76.14%PRTGPortage Biotech13.36%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%GLMDGalmed Pharmaceuticals19.80%PRTGPortage Biotech42.07%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million12.62 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionablePRTGPortage Biotech61.05 million608,000OptionableSNSESensei Biotherapeutics4025.21 million19.62 millionNot OptionableGLMD, PRTG, SNSE, and AIMD HeadlinesRecent News About These CompaniesBrokers Issue Forecasts for SNSE Q2 EarningsJune 6 at 1:15 AM | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) vs. Elite Pharmaceuticals (OTCMKTS:ELTP) Critical ContrastJune 4, 2025 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Now Covered by Analysts at HC WainwrightJune 3, 2025 | americanbankingnews.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comSensei Biotherapeutics provides update, highlights key upcoming milestonesJanuary 9, 2025 | markets.businessinsider.comPromising Outlook for Sensei Biotherapeutics: Buy Rating Backed by SNS-101 Development and Financial ProjectionsJanuary 9, 2025 | markets.businessinsider.comSensei Biotherapeutics Inc (SNSE) Stock Trading RecapJanuary 9, 2025 | bovnews.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, PRTG, SNSE, and AIMD Company DescriptionsAinos NASDAQ:AIMD$0.66 +0.01 (+1.76%) As of 06/6/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Galmed Pharmaceuticals NASDAQ:GLMD$1.51 +0.02 (+1.34%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.51 0.00 (-0.07%) As of 06/6/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Portage Biotech NASDAQ:PRTG$8.41 +0.03 (+0.36%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$8.46 +0.04 (+0.54%) As of 06/6/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Sensei Biotherapeutics NASDAQ:SNSE$0.34 -0.02 (-4.65%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.35 +0.01 (+1.69%) As of 06/6/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
